{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"46"}]}],"title":"Immunogenicity-evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"23"}]}],"title":"Baseline Negative: ATA negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"19"}]}],"title":"Baseline Negative: ATA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}]}],"title":"Baseline Negative: Transiently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"title":"Baseline Negative: Persistently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"title":"Baseline Negative: Neutralizing ATA Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Baseline Positive: ATA Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Baseline Positive: ATA Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Baseline Positive: Transiently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Baseline Positive: Persistently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Baseline Positive: Neutralizing ATA Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.","groups":[{"description":"Participants with pcALCL received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"pcALCL: Brentuximab Vedotin"},{"description":"Participants with MF received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG001","title":"MF: Brentuximab Vedotin 1.8 mg/kg"}],"paramType":"NUMBER","populationDescription":"The Safety population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to End of Treatment (Week 52)","title":"Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin","type":"SECONDARY","unitOfMeasure":"participants"}